Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.54 USD | -1.28% | -.--% | +79.28% |
Sales 2026 * | - | Sales 2027 * | - | Capitalization | 129M 175M |
---|---|---|---|---|---|
Net income 2026 * | - | Net income 2027 * | - | EV / Sales 2026 * | - |
Net cash position 2026 * | - 0 | Net cash position 2027 * | - 0 | EV / Sales 2027 * | - |
P/E ratio 2026 * |
-
| P/E ratio 2027 * |
-
| Employees | 138 |
Yield 2026 * |
-
| Yield 2027 * |
-
| Free-Float | 98.11% |
Latest transcript on NGM Biopharmaceuticals, Inc.
1 day | -1.28% | ||
3 months | +0.65% | ||
6 months | +156.54% | ||
Current year | +79.28% |
Managers | Title | Age | Since |
---|---|---|---|
David Woodhouse
CEO | Chief Executive Officer | 54 | 15-03-01 |
William Rieflin
CHM | Chairman | 64 | 10-08-31 |
Daniel Kaplan
CTO | Chief Tech/Sci/R&D Officer | - | 07-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Roger Perlmutter
BRD | Director/Board Member | 71 | 21-06-07 |
David Goeddel
BRD | Director/Board Member | 72 | 07-12-31 |
William Rieflin
CHM | Chairman | 64 | 10-08-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.04% | 0 M€ | 0.00% | - | |
0.02% | 0 M€ | 0.00% | - | |
0.00% | 9 M€ | -.--% | - |
1st Jan change | Capi. | |
---|---|---|
+79.28% | 129M | |
+9.42% | 115B | |
+11.84% | 106B | |
-2.53% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- NGM Stock